Calquence (acalabrutinib)

pCPA File Number: 21413

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0211-000

pCPA Engagement Letter Issued:

2021-05-27

Negotiation Process Concluded:

2021-10-05